API | reparixin

reparixin Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Now

Chemistry

SMILES: CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(=O)(=O)C
InChIKey: KQDRVXQXKZXMHP-LLVKDONJSA-N
Mol. Mass: 283.39
ALogP: 2.06 Partition coefficient
ChEMBL Molecule:
reparixin

More Chemistry

Pharmacology

Mechanisms of Action:
- C-X-C chemokine receptor type 1 (Homo sapiens) ^UniProt
- C-X-C chemokine receptor type 2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

2-(4-isobutylphenyl)propionylmethanesulfonamide | df-1681y | (r)-2-(4-isobutylphenyl)propionylmethanesulfonamide | reparixin | repertaxin

Organizations (21)

Research & Development (21)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (13)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (13)

Allografts (Phase 2)

Breast Neoplasms (Phase 2)

COVID-19 (Phase 3)

Diabetes Mellitus, Type 1 (Phase 3)

Fatigue (Phase 2)

Kidney Diseases (Phase 2)

Lung Transplantation (Phase 2)

Pancreatic Neoplasms (Phase 2)

Pancreatitis (Phase 2/Phase 3)

Pneumonia (Phase 3)

Pneumonia, Viral (Phase 3)

Reperfusion Injury (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 15
# of Trial Organizations: 21

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue